Novavax Secures US DoD Contract for 10 Million Doses of COVID-19 Vaccine

Novavax, Inc. (Gaithersburg, MD, USA) has been awarded a contract by the US Department of Defense (DoD) for the manufacturing of NVX‑CoV2373, the company’s COVID-19 vaccine candidate.

NVX‑CoV2373 consists of a stable, prefusion protein antigen made using Novavax’s proprietary nanoparticle technology and includes the company’s proprietary Matrix‑M adjuvant. JPEO-CRBND-EB through funding provided by the Defense Health Program, has agreed to fund up to USD 60 million to support Novavax in its production of several components of the vaccine that will be manufactured in the US. The agreement includes a 2020 delivery of 10 million doses of NVX‑CoV2373 for DoD that could be used in Phase 2/3 clinical trials or under an Emergency Use Authorization (EUA) if approved by the US FDA. As part of the contract, Novavax will work with a US-based biologics contract development manufacturing organization (CDMO) to manufacture the antigen component of NVX-CoV2373 for at least 10 million doses of vaccine. Novavax will also collaborate with US-based CDMOs to scale up production and manufacture of the Matrix-M adjuvant component of the vaccine.


“We are genuinely honored at the opportunity to protect our military personnel and their families who have devoted themselves to the needs of U.S. citizens and others worldwide,” said Stanley C. Erck, President and CEO of Novavax. “Importantly, this award will allow Novavax to significantly expand its US production capacity of NVX-CoV2373, a critical step in our ability to provide vaccine support to the COVID-19 pandemic.”


Related Links:
Novavax, Inc.